Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
The FDA has granted a priority review designation to a supplemental biologics license application for Zejula for the treatment of certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer.
Patients with ovarian cancerwho experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects. Luckily, doctors have a variety of ways to relieve or prevent these discomforts. At the same time, scientists are working to develop new treatments that may be both efficacious and easier for patients to tolerate.
"We hope that this array of articles, while offering comprehensive information about cutting-edge treatments, will also serve as a reminder of the shared experience of those in the cancer community and the sense of connection it can bring," said Chairman and CEO, Mike Hennessy, Sr.